The journal retracts the 16 February 2022 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.
This retraction was approved by the Chief Editors of Frontiers in Pediatrics and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Summary
Citation
Frontiers Editorial Office (2025) Retraction: ORMDL3 promotes angiogenesis in chronic asthma through the ERK1/2/VEGF/MMP-9 pathway. Front. Pediatr. 13:1640136. doi: 10.3389/fped.2025.1640136
Received
03 June 2025
Accepted
03 June 2025
Published
16 June 2025
Approved by
Jordi Pérez-Tur, Spanish National Research Council (CSIC), Spain
Volume
13 - 2025
Updates
Copyright
© 2025 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.